2.00

2.04% +0.04

Pre-market: 2.00

CytomX Therapeutics Inc (CTMX)

Overview News Price History Option Chain Financials Discussions Forecast

CytomX Therapeutics Inc stock is currently priced at $2.00, with a 24-hour trading volume of 3.26M. It has seen a +2.04% increased in the last 24 hours and a +7.53% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.97 pivot point. If it approaches the $2.00 resistance level, significant changes may occur.

Previous Close:

$1.96

Open:

$1.98

24h Volume:

3.26M

Market Cap:

$155.84M

Revenue:

$101.21M

Net Income/Loss:

$-569.00K

P/E Ratio:

-2.381

EPS:

-0.84

Net Cash Flow:

$-56.88M

1W Performance:

-1.96%

1M Performance:

+7.53%

6M Performance:

+55.04%

1Y Performance:

+13.64%

1D Range:

$1.93

$2.01

52W Range:

$1.04

$5.85

CytomX Therapeutics Inc Stock (CTMX) Company Profile

Name

CytomX Therapeutics Inc

Sector

Healthcare (1211)

Industry

Biotechnology (697)

Phone

650-515-3185

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA

Employee

Twitter

@cytomxinc

Next Earnings Date

2024-05-15

Latest SEC Filings

CTMX's Discussions on Twitter

CytomX Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-14-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-07-22	Downgrade	Jefferies	Buy → Hold
Jul-07-22	Downgrade	Mizuho	Buy → Neutral
Jul-07-22	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-22	Downgrade	Wedbush	Outperform → Neutral
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Jan-18-22	Upgrade	Barclays	Underweight → Overweight
Nov-15-21	Initiated	BTIG Research	Buy
May-28-21	Downgrade	Barclays	Equal Weight → Underweight
Mar-29-21	Initiated	JP Morgan	Overweight
Mar-23-21	Upgrade	Jefferies	Hold → Buy
Sep-22-20	Downgrade	Guggenheim	Buy → Neutral
Jun-01-20	Downgrade	Jefferies	Buy → Hold
May-14-20	Reiterated	H.C. Wainwright	Buy
Mar-24-20	Upgrade	Wedbush	Neutral → Outperform
Mar-04-20	Initiated	Barclays	Equal Weight
Nov-20-19	Initiated	Guggenheim	Buy
Nov-11-19	Downgrade	Wedbush	Outperform → Neutral
Jun-13-19	Initiated	Mizuho	Buy
May-14-19	Initiated	Cantor Fitzgerald	Overweight
Mar-11-19	Initiated	Barclays	Overweight
Nov-26-18	Initiated	Piper Jaffray	Overweight
Oct-15-18	Initiated	Goldman	Neutral
Sep-13-18	Initiated	H.C. Wainwright	Buy
Jun-01-18	Initiated	SunTrust	Buy
Jan-05-18	Initiated	Citigroup	Buy
Sep-08-17	Initiated	Wedbush	Outperform
Mar-27-17	Initiated	H.C. Wainwright	Buy
Mar-02-17	Initiated	Instinet	Buy
Jan-03-17	Downgrade	Oppenheimer	Outperform → Perform
Nov-02-15	Initiated	Oppenheimer	Outperform

View All

CytomX Therapeutics Inc Stock (CTMX) Latest News

CytomX Therapeutics Announces New Employment Inducement Grants - Yahoo Finance

Yahoo Finance

CytomX Therapeutics Inc [CTMX] stock for 42175 USD was sold by McCarthy Sean A. – Knox Daily - Knox Daily

Knox Daily

CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Canada Shine On

Yahoo Canada Shine On

Top investors say CytomX Therapeutics Inc (CTMX) ticks everything they need – Sete News - SETE News

SETE News

Top Ranked Momentum Stocks to Buy for April 17th - Yahoo Movies UK

Yahoo Movies UK

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Are Not Doing Enough For Some Investors - Yahoo News Australia

Yahoo News Australia

CytomX Therapeutics Inc Stock (CTMX) Financials Data

CytomX Therapeutics Inc (CTMX) Revenue 2024

CTMX reported a revenue (TTM) of $101.21 million for the quarter ending December 31, 2023, a +90.38% rise year-over-year.

CytomX Therapeutics Inc (CTMX) Net Income 2024

CTMX net income (TTM) was -$569.00 thousand for the quarter ending December 31, 2023, a +99.43% increase year-over-year.

CytomX Therapeutics Inc (CTMX) Cash Flow 2024

CTMX recorded a free cash flow (TTM) of -$56.88 million for the quarter ending December 31, 2023, a +49.46% increase year-over-year.

CytomX Therapeutics Inc (CTMX) Earnings per Share 2024

CTMX earnings per share (TTM) was -$0.02 for the quarter ending December 31, 2023, a +98.68% growth year-over-year.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.